The heterogeneity of the demographic data, nature and stage of kidney disease, as well as the severity of liver injury and extrahepatic manifestations may lead to different results, and it remains unknown whether IFN-based dual therapy with IFN plus RBV, the main components of HCV treatment in mainland China due to the high cost of direct-acting antiviral agents (DAAs), can improve renal function or reverse CKD in HCV-infected patients in a Chinese population. Here, IFNA1 is linked to kidney disorder.